The online version of this article (doi:10.1186/s12885-017-3185-9) contains supplementary material, which is available to authorized users.
Jose Angel Garcia-Saenz, Fernando Moreno, Vanesa Garcia-Barberan, Eduardo Diaz-Rubio and Trinidad Caldes are members of CIBERONC network.
Accurate measurement of tumor burden in breast cancer disease is essential to improve the clinical management of patients. In this study, we evaluate whether the fluctuations in the fraction of PIK3CA mutant allele correlates with tumor response according to RECIST criteria and tumor markers quantification.
Eighty six plasma samples were analyzed by digital PCR using Rare Mutation Assays for E542K, E545K and H1047R. Mutant cfDNA and tumor markers CA15-3 and CEA were compared with radiographic imaging.
The agreement between PIK3CA mutation status in FFPE samples and circulating tumor DNA (ctDNA) was moderate (K = 0.591; 95% IC = 0.371–0.811). Restricting the analysis to the metastatic patients, we found a good agreement between PIK3CA mutation status assessed in liquid and solid biopsy (K = 0.798 95%; IC = 0.586–1). ctDNA showed serial changes with fluctuations correlating with tumor markers 15.3 and CEA in 7 out of 8 cases with Pearson correlation coefficients ranging from 0.99 to 0.46 and from 0.99 to 0.38 respectively. Similarly, fluctuations in the fraction of PIK3CA mutant allele always correlated with changes in lesion size seen on images, although in two cases it did not correlate with treatment responses as defined by RECIST criteria.
oncogenic mutation quantification in plasma samples can be useful to monitor treatment outcome. However, it might be limited by tumor heterogeneity in advanced disease and it should be evaluated together with radiographic imaging.
Additional file 1: Clinical and pathological variables. (XLSX 16 kb)12885_2017_3185_MOESM1_ESM.xlsx
Additional file 2: Limit of detection and limit of quantification estimation according to ICH guidelines. (XLSX 30 kb)12885_2017_3185_MOESM2_ESM.xlsx
Additional file 3: Performance of PIK3CA assays on cfDNA. Data from sample chips are displayed in a scatter plot based on color of FAM and VIC events. Plots A, C and E correspond to a negative samples. Plots B, D and F correspond to positive samples for the H1047R, E545K and E542K mutation respectively. The mutation is labeled with FAM (blue data points) whereas wild-type is labeled with VIC (red data points). Yellow cluster represent the no amplification cluster. (PPTX 153 kb)12885_2017_3185_MOESM3_ESM.pptx
Additional file 4: Serial plasma PIK3CA mutation levels and treatment outcome, assessed according to RECIST criteria v.1.1. SD = stable disease, PR = partial response, PD = progressive disease of individual cases. (PPTX 78 kb)12885_2017_3185_MOESM4_ESM.pptx
Diamantis A, Magiorkinis E, Koutselini H. Fine-needle aspiration (FNA) biopsy: historical aspects. Folia Histochem Cytobio. 2003;47:191–7.
Wang JY, Hsieh JS, Chang MY, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28:721–6. PubMed
Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014;120:3896–901. CrossRefPubMedPubMedCentral
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumour. Nature. 2012;490:61–70. CrossRef
Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl. 2014;6:224ra24. CrossRef
- Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging
José Angel García-Saenz
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II